Eli Lilly reported pivotal Phase 3 data showing its triple-agonist obesity candidate delivered unprecedented weight loss but drove higher-than-expected discontinuation rates. Company-released and conference-ready results tied retatrutide to mean weight reductions approaching the high-20s percentage range in trial cohorts and large pain-score improvements in a knee osteoarthritis subgroup. Investigators and analysts flagged the combination of outsized efficacy and tolerability signals: many participants exited the study early, some because of adverse effects and others because of rapid weight loss. Data were presented at major scientific briefings and in company releases; full datasets and safety splits are pending. The readout puts substantial commercial and clinical pressure on competing GLP-1 and multi-agonist programs while prompting questions about dose optimization, long-term safety, and real-world discontinuations. Clinicians and payers will be watching detailed safety tables and discontinuation reasons when the full study report and regulatory filings appear.